Neoleukin Therapeutics (NLTX) Prices 8.925M Share Offering at $8.40/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
After-Hours Movers 12/17: (SCS) (CTAS) (NE) Higher; (FIXX) (PACB) (FDX) Lower (more...)
December 17, 2019 6:00 PM ESTToday's After-Hours Movers
Homology Medicines, Inc. (NASDAQ: FIXX) 20.2% LOWER; announced today promising initial clinical data from the first gene therapy clinical trial in phenylketonuria (PKU). The pheNIX trial is a Phase 1/2 randomized, concurrently controlled, dose-escalation study for adults with PKU. As of December 2, 2019, two patients had received investigational HMI-102 gene therapy in Cohort 1 (low-dose) and one patient in Cohort 2 (mid-dose). Preliminary safety data from Cohorts 1 and 2 showed HMI-102 was well-tolerated. Efficacy data from the first patient in Cohort 2 indicated a dose-response effect with an observed reduction in... More
Neoleukin Therapeutics (NLTX) Announces Proposed $50M Public Offering of Common Stock
December 17, 2019 4:38 PM EST(Updated - December 17, 2019 4:39 PM EST)
Neoleukin Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to $50.0 million of shares of its common stock in an... More
